Health & Biotech
NSB (ASX:NSB) is a drug development company focused on developing peptide-based pharmaceutical drugs for the treatment of neurodegenerative conditions with high unmet medical need.
The NSB product portfolio includes several therapeutic peptides that are modeled on the domains of a naturally occurring protein called Metallothionein-II (MT-II).
EmtinB is the lead candidate that has shown to closely mimic the neuroprotective and neuroregenerative ability of MT-II and is currently being developed as a treatment for neurodegenerative dementia and Alzheimer’s disease, and degenerative conditions of the optic nerve.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Neuroscientific says EmtinB shows positive signs, expects full results in H2
Health & Biotech
ASX Health Stocks: Orthocell reports positive results from nerves reconstruction trial
Health & Biotech
ASX Health Stocks: Integral goes big in Queensland, Credit Suisse says it’s time to choose between HLS and ACL
Health & Biotech
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly
News
Closing Bell: Small caps go full Maximus, unleash gains in face of rising broad-based fears
News
ASX Health Stocks: OncoSil rips higher as its device goes live in Spain
Health & Biotech
ASX Health Stocks: Neuroscientific announces breakthrough as Neuren gets ready for Phase 2 trial
News
Market Highlights and 5 ASX Small Caps to watch on Friday
News
Market Highlights and 5 ASX Small Caps to watch on Tuesday
Health & Biotech
ASX Health Stocks: OncoSil and Neuroscientific Biopharma release positive clinical results
News
Market Highlights and 5 ASX Small Caps to watch on Friday
Health & Biotech
ASX Health Stocks: Proteomics jumps 13pc on diabetes test
Health & Biotech
ASX Health Stocks: Neuroscientific pockets $25m R&D incentive, MGC Pharma jumps 15% on India approval for COVID-19 drug
Health & Biotech
Neuroscientific Biopharmaceuticals says EmtinB shows promise as a multiple sclerosis treatment
News
Market Highlights and 5 ASX Small Caps to watch on Tuesday
Health & Biotech
ASX Health Stocks: Nanosonics jumps almost 20% as revenue momentum picks up steam
Health & Biotech